Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Swanson

Orthopaedic Trauma Reno, NV Medical Doctor

NPI 1407147556 CMS profile 2220903

555 N Arlington Ave, Reno, NV 89503

Open in the dashboard

General payments

$2,525

22 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$35,000

1 holding reported · through program year 2025

Research they led as principal investigator

$10,860 paid to institutions, not to them · program years 2023–2024

Through program year 2025, David Swanson of Reno, NV is reported in the CMS Open Payments database as having received $2,525 across 22 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,860 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $35,000 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 25th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $165 1
2024 General $23 1
2023 General $344 2
2022 General $84 3
2021 General $1,369 4
2020 General $94 1
2019 General $447 10
2022 Ownership $35,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Swanson
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to David Swanson were reported at $165. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year David Swanson Orthopaedic Trauma median Middle half National median
2019 $447 $1,475 $264–$6,401 $163
2020 $94 $596 $120–$4,020 $114
2021 $1,369 $919 $171–$4,697 $132
2022 $84 $1,547 $272–$7,240 $149
2023 $344 $1,330 $247–$5,875 $160
2024 $23 $1,288 $277–$6,797 $164
2025 $165 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sequoia Surgical, Inc. $1,212 2 payments
  2. Stryker Corporation $668 12 payments
  3. DePuy Synthes Sales Inc. $297 4 payments
  4. Exactech, Inc. $185 1 payment
  5. Acumed LLC $125 1 payment
  6. Abbott Laboratories $23 1 payment
  7. Musculoskeletal Transplant Foundation Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,280 16 payments
  2. Education $1,200 1 payment
  3. Travel and Lodging $45 5 payments
Products named General payments · program years 2019–2025
  1. MAKO $243 7 payments
  2. Equinoxe $185 1 payment
  3. T2 ALPHA $159 1 payment
  4. Anatomic Radial Head System $125 1 payment
  5. RibLoc $125 1 payment
  6. BioBridge $125 1 payment
  7. Clavicle Plating System $125 1 payment
  8. Polarus 3 Solution $125 1 payment
  9. TFN ADVANCED $121 2 payments
  10. GLOBAL $94 1 payment
  11. Other $206 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

55

Median for Orthopedic Surgery: 203

Drug cost

$285

Median for Orthopedic Surgery: $1,433

Branded share of claims

54.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 30 $210
Tramadol Hcl Generic 13 $45
Meloxicam Generic 12 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$173,839

Medicare's payments for the services billed

Medicare patients

302

Average age 77

Services billed

849

207 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 33%
Osteoporosis 30%
Diabetes 29%
Ischemic heart disease 29%
Chronic kidney disease 26%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record